John Geddes - Selected Publications#

1. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021 May;8(5):416-427. doi: 10.1016/S2215-0366(21)00084-5. (Scopus Dec 2022 638 citations)

Large observational study using innovative methods and providing urgently needed evidence on CNS sequelae of COVID-19 infection

2. Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., . . . Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.. Lancet, 391(10128), 1357-1366 (Scopus Dec 2022 1293 citations)

Highly cited, influential and innovative sysnthesis of comparative evidence across currently available antidepressant drugs

3. Geddes, J. R., Gardiner, A., Rendell, J., Voysey, M., Tunbridge, E., Hinds, C., . . . CEQUEL Investigators and Collaborators. (2016). Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial.. Lancet Psychiatry, 3(1), 31-39. (Scopus Dec 2022 62 citations)

Innovative and successful trial providing much need evidence on lamotrigine - and unexpected potential negative interaction with folate

4. Geddes, J. R., & Miklowitz, D. J. (2013). Bipolar Disorder Treatment of bipolar disorder. The Lancet, 381(9878), 1672-1682. doi:10.1016/S0140-6736(13)60857-0 (Scopus Dec 2022 489 citations)

Invited overview of current state of evidence

5. McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012). Lithium toxicity profile: a systematic review and meta-analysis.. Lancet (London, England), 379(9817), 721-728. doi:10.1016/s0140-6736(11)61516-x (Scopus Dec 2022 559 citations)

Huge synthesis of evidence concerning lithium toxicity

6. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Ostacher MJ, Morriss R, Alder N, Juszczak E for the BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet,2010, 375, 385-395 (Scopus Dec 2022 402 citations)

Largest long term 4 country (UK, France, Italy, US) trial comparing lithium and valproate alone and in combination

7. Fazel, S., Khosla, V., Doll, H., & Geddes, J. (2008). The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis.. PLoS medicine, 5(12), e225. doi:10.1371/journal.pmed.0050225 2 (Scopus Dec 2022 693 citations)

Building on long term contribution to this neglected, highly disadvantaged group.

8. Geddes J.R. et al for the UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.. Lancet (London, England), 361(9360), 799-808. doi:10.1016/s0140-6736(03)12705-5 (Scopus Dec 2022 1196 citations)

State of the art overview of evidence on ECT, highly cited internationally

9. Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review.. Lancet (London, England), 361(9358), 653-661. doi:10.1016/s0140-6736(03)12599-8 (Scopus Dec 2022 678 citations)

Influential research synthesis yielding unexpectedly strong evidence for long term treatment with antidepressants

10. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.. BMJ (Clinical research ed.), 321(7273), 1371-1376. doi:10.1136/bmj.321.7273.1371 (Scopus Dec 2022 962 citations)

Important research synthesis highlighting limitations of evidence for presumed superiority of atypical antipsychotics - used as key reference to make case for NIMH CATIE and NIHR CUTLASS trials